FDA accepts QR Pharma bisnorcymserine IND
The compound targets AD via selective butyrylcholinesterase inhibition (BChEI) as well as with a disease modifying activity via amyloid precursor protein (APP) inhibition. QR Pharma has completed all
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).